Global Biotech Weekly

This week, we will focus on the critical near-term catalysts anticipated in the immediate term over the next two months. Nektar Therapeutics (NASDAQ: NKTR) is a biotechnology company with a market cap of about US$196m and a cash balance of approximately US$179m. The company has a history of developi NKTR runs two separate Phase 2b trials with rezpegaldesleukin (LY3471851), an IL-2 pathway agonist. One trial (REZOLVE-AA) targets severe to very severe alopecia areata (AA), with Lyra Therapeutics (NASDAQ: LYRA) is developing therapies for chronic rhinosinusitis (CRS), a highly prevalent inflammatory disease. The company has a market cap of around US$26m a The Phase 3 ENLIGHTEN II trial is evaluating LYR-210 in surgically naïve patients with CRS. This study resumed enrollment on 25 April 2023, and is expected to complete enrollment Theriva Biologics (NYSE: TOVX) is a micro-cap clinical-stage company focused on oncolytic virus therapies, with a market cap of approximately US$5.6m. The company has limited cash The VIRAGE trial is a Phase 2b/3 clinical study of VCN-01 in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), a cancer with extremely poor prognosis. The drug hol